{"brief_title": "Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)", "brief_summary": "The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).", "condition": ["Macular Degeneration", "Maculopathy, Age-Related", "Age-Related Maculopathies", "Age-Related Maculopathy", "Maculopathies, Age-Related"], "intervention_type": ["Drug", "Other"], "intervention_name": ["Anecortave Acetate 15 mg sterile suspension", "Anecortave Acetate Vehicle"], "description": ["0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection", "Administered as a posterior juxtascleral injection"], "arm_group_label": ["Anecortave Acetate", "Anecortave Acetate Vehicle"], "criteria": "Inclusion Criteria: - Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Under 50 years. - Other protocol-defined exclusion criteria may apply.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Maculopathies, Age-Related", "mesh_term": ["Macular Degeneration", "Choroidal Neovascularization", "Neovascularization, Pathologic", "Anecortave", "Hydrocortisone"], "id": "NCT00051129"}